The Cooper Companies, Inc. $COO Stock Holdings Lifted by Engineers Gate Manager LP

Key Points

• Engineers Gate Manager LP increased its Cooper Companies stake by 8,637.7% in the second quarter, bringing its holdings to 249,897 shares valued at approximately $17.9 million. Institutional investors own 24.39% of the company.
• Cooper Companies reported quarterly adjusted EPS of $1.15, narrowly exceeding estimates, while revenue of about $1.07 billion fell short of consensus. Management’s fiscal 2026 EPS guidance of $4.51–$4.55 is below analysts’ $4.63 expectation.
• The board authorized a $3 billion share-repurchase program, allowing buybacks of up to 22.7% of outstanding shares. Analysts’ consensus rating is “Hold,” with an average price target of $81.64.

Engineers Gate Manager LP grew its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 8,637.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 249,897 shares of the medical device company's stock after acquiring an additional 247,037 shares during the period. Engineers Gate Manager LP owned about 0.13% of Cooper Companies worth $17,920,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Cooper Companies by 48.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company's stock worth $1,890,000 after acquiring an additional 7,363 shares during the last quarter. First Trust Advisors LP increased its stake in Cooper Companies by 115.8% in the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company's stock worth $9,702,000 after purchasing an additional 73,165 shares in the last quarter. Cresset Asset Management LLC acquired a new stake in Cooper Companies during the 2nd quarter worth about $291,000. Cerity Partners LLC lifted its stake in Cooper Companies by 4.4% during the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company's stock valued at $1,272,000 after buying an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Cooper Companies by 2.8% during the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company's stock valued at $2,551,000 after buying an additional 973 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on COO. Needham & Company LLC decreased their target price on shares of Cooper Companies from $101.00 to $86.00 and set a "buy" rating for the company in a report on Friday, June 5th. Wall Street Zen upgraded shares of Cooper Companies from a "hold" rating to a "buy" rating in a research report on Sunday, June 21st. Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the stock an "outperform" rating in a research note on Thursday, June 4th. Piper Sandler set a $86.00 price objective on shares of Cooper Companies and gave the stock an "overweight" rating in a research report on Monday, June 1st. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Cooper Companies in a research note on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $81.64.

Cooper Companies Stock Performance

COO stock opened at $63.48 on Thursday. The firm has a 50 day moving average of $72.42 and a two-hundred day moving average of $70.02. The Cooper Companies, Inc. has a 12 month low of $58.89 and a 12 month high of $89.83. The company has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter last year, the firm earned $0.49 EPS. Cooper Companies's revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Cooper Companies announced that its board has authorized a stock buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

Cooper Companies Company Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.